Cargando…
Tolerability and effectiveness of albuvirtide combined with dolutegravir for hospitalized people living with HIV/AIDS
Treatment options for hospitalized people living with HIV/AIDS (PLWHA) with opportunistic infections and comorbidities are limited in China. Albuvirtide (ABT), a new peptide drug, is a long-acting HIV fusion inhibitor with limited drug-drug interactions and fast onset time. This single-center, retro...
Autores principales: | Liu, Huanxia, He, Shenghua, Yang, Tongtong, Lu, Chunrong, Yao, Yuan, Zhou, Ruifeng, Yin, Ke, He, Yuanhong, Cheng, Jing |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10637561/ https://www.ncbi.nlm.nih.gov/pubmed/37960773 http://dx.doi.org/10.1097/MD.0000000000035344 |
Ejemplares similares
-
Impact of previous HIV resistance and virologic failures on virologic outcome following a switch to dolutegravir with 2 NRTIs among people living with HIV
por: Sangaré, Mohamed N’dongo, et al.
Publicado: (2020) -
Effect of Dolutegravir regimen against other regimens on some hematological parameters, CD4 count and viral load of people living with HIV infection in South Eastern Nigeria
por: Echefu, Stella N., et al.
Publicado: (2023) -
Trends & predictors of non-AIDS comorbidities among people living with HIV and receiving antiretroviral therapy in Lebanon
por: Abou Hassan, Farouk F., et al.
Publicado: (2022) -
Two case reports of severe myocarditis associated with the initiation of dolutegravir treatment in HIV patients
por: Mahlab-Guri, Keren, et al.
Publicado: (2016) -
Real-world efficacy and safety of dolutegravir plus lamivudine versus tenofovir plus lamivudine and efavirenz in ART-naïve HIV-1-infected adults
por: Li, Jin, et al.
Publicado: (2022)